Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.
Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, Griffin JD. Stone RM, et al. Among authors: griffin jd. Ann Hematol. 2004;83 Suppl 1:S89-90. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124689 Clinical Trial. No abstract available.
ARG tyrosine kinase activity is inhibited by STI571.
Okuda K, Weisberg E, Gilliland DG, Griffin JD. Okuda K, et al. Among authors: griffin jd. Blood. 2001 Apr 15;97(8):2440-8. doi: 10.1182/blood.v97.8.2440. Blood. 2001. PMID: 11290609 Free article.
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.
Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, Gray N. Weisberg E, et al. Among authors: griffin jd. Leukemia. 2012 Oct;26(10):2233-44. doi: 10.1038/leu.2012.96. Epub 2012 Apr 3. Leukemia. 2012. PMID: 22469781 Free PMC article.
Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML.
Wu H, Wang A, Qi Z, Li X, Chen C, Yu K, Zou F, Hu C, Wang W, Zhao Z, Wu J, Liu J, Liu X, Wang L, Wang W, Zhang S, Stone RM, Galinsky IA, Griffin JD, Weinstock D, Christodoulou A, Wang H, Shen Y, Zhai Z, Weisberg EL, Liu J, Liu Q. Wu H, et al. Among authors: griffin jd. Leukemia. 2016 Oct;30(10):2112-2116. doi: 10.1038/leu.2016.151. Epub 2016 May 25. Leukemia. 2016. PMID: 27220667 Free PMC article. No abstract available.
Smac mimetics: implications for enhancement of targeted therapies in leukemia.
Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D, Straub C, Zawel L, Daley JF, Lazo-Kallanian S, Stone R, Galinsky I, Frank D, Kung AL, Griffin JD. Weisberg E, et al. Among authors: griffin jd. Leukemia. 2010 Dec;24(12):2100-9. doi: 10.1038/leu.2010.212. Epub 2010 Sep 16. Leukemia. 2010. PMID: 20844561 Free PMC article.
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.
Wu H, Hu C, Wang A, Weisberg EL, Wang W, Chen C, Zhao Z, Yu K, Liu J, Wu J, Nonami A, Wang L, Wang B, Stone RM, Liu S, Griffin JD, Liu J, Liu Q. Wu H, et al. Among authors: griffin jd. Leukemia. 2016 Mar;30(3):754-7. doi: 10.1038/leu.2015.175. Epub 2015 Jul 3. Leukemia. 2016. PMID: 26139428 Free PMC article. No abstract available.
Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.
Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q. Wu H, et al. Among authors: griffin jd. Leukemia. 2016 Jan;30(1):173-81. doi: 10.1038/leu.2015.180. Epub 2015 Jul 13. Leukemia. 2016. PMID: 26165234 Free PMC article.
Drug resistance in mutant FLT3-positive AML.
Weisberg E, Sattler M, Ray A, Griffin JD. Weisberg E, et al. Among authors: griffin jd. Oncogene. 2010 Sep 16;29(37):5120-34. doi: 10.1038/onc.2010.273. Epub 2010 Jul 12. Oncogene. 2010. PMID: 20622902 Review.
Point mutations in the FLT3 gene in AML.
Griffin JD. Griffin JD. Blood. 2001 Apr 15;97(8):2193A-2193. doi: 10.1182/blood.v97.8.2193a. Blood. 2001. PMID: 11290575 No abstract available.
545 results